Provided by Tiger Trade Technology Pte. Ltd.

Biocryst Pharmaceuticals

7.61
+0.20002.70%
Post-market: 7.42-0.1900-2.50%19:49 EST
Volume:3.55M
Turnover:26.98M
Market Cap:1.60B
PE:-167.92
High:7.69
Open:7.40
Low:7.35
Close:7.41
52wk High:11.31
52wk Low:6.00
Shares:210.74M
Float Shares:207.69M
Volume Ratio:0.78
T/O Rate:1.71%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0453
EPS(LYR):-0.4300
ROE:587.33%
ROA:10.31%
PB:-4.13
PE(LYR):-17.70

Loading ...

BioCryst (BCRX) Receives a Buy from Wedbush

TIPRANKS
·
Nov 19

Assessing BioCryst Pharmaceuticals (BCRX) Valuation After Promising Pediatric ORLADEYO Trial Results and FDA Review Updates

Simply Wall St.
·
Nov 19

BioCryst Director Machelle Sanders Reports Sale of Common Shares

Reuters
·
Nov 18

Did BioCryst's (BCRX) ORLADEYO Revenue Guidance and Pediatric Data Just Shift Its Investment Narrative?

Simply Wall St.
·
Nov 15

BioCryst to Acquire Astria Therapeutics for $8.55 Per Share and Stock

Reuters
·
Nov 12

BioCryst Unveils Data Showing ORLADEYO Cuts HAE Attacks in Children in Yearlong Trial

Reuters
·
Nov 06

BioCryst Presents New Data at Acaai Highlighting Burden of Hae on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated With One Year of Orladeyo® (Berotralstat)

THOMSON REUTERS
·
Nov 06

Stock Track | BioCryst Pharmaceuticals Soars 5.03% Pre-Market on Conference Presentation and Positive Analyst Rating

Stock Track
·
Nov 05

Stock Track | BioCryst Pharmaceuticals Plummets 5.03% as Analysts Cut Price Targets

Stock Track
·
Nov 04

BioCryst Pharmaceuticals Is Maintained at Buy by Needham

Dow Jones
·
Nov 04

Barclays Sticks to Their Hold Rating for BioCryst (BCRX)

TIPRANKS
·
Nov 04

U.S. RESEARCH ROUNDUP-Affiliated Managers Group, Argenx, Cardinal Health

Reuters
·
Nov 04

BioCryst Pharmaceuticals Inc : Needham Cuts Target Price to $18 From $20

THOMSON REUTERS
·
Nov 04

BioCryst (BCRX) Gets a Buy from Needham

TIPRANKS
·
Nov 04

Stock Track | BioCryst Pharmaceuticals Plummets 5.33% as Q3 Revenue Misses Estimates Despite EPS Beat

Stock Track
·
Nov 03

BioCryst Pharmaceuticals Q3 EPS USD 0.06

Reuters
·
Nov 03

BioCryst reports Q3 adjusted EPS 16c, consensus 8c

TIPRANKS
·
Nov 03

BioCryst Pharma Q3 Adj. EPS $0.16 Beats $0.04 Estimate, Sales $159.395M Miss $162.974M Estimate

Benzinga
·
Nov 03

BioCryst Pharmaceuticals reports Q3 ORLADEYO net revenue of $159.1 million and operating profit of $29.6 million

Reuters
·
Nov 03

BioCryst Pharmaceuticals Inc: Raising Its Outlook for Full Year 2025 Global Net Orladeyo Revenue to Between $590 Mln and $600 Mln

THOMSON REUTERS
·
Nov 03